Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‘CREATE’
Titel:
Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‘CREATE’
Auteur:
Schöffski, P. Wozniak, A. Kasper, B. Aamdal, S. Leahy, M.G. Rutkowski, P. Bauer, S. Gelderblom, H. Italiano, A. Lindner, L.H. Hennig, I. Strauss, S. Zakotnik, B. Anthoney, A. Albiges, L. Blay, J.-Y. Reichardt, P. Sufliarsky, J. van der Graaf, W.T.A. Debiec-Rychter, M. Sciot, R. Van Cann, T. Marréaud, S. Raveloarivahy, T. Collette, S. Stacchiotti, S.